8. Dr. Reddy's Laboratories (RDY) is an integrated pharmaceutical company focusing on global generics, pharmaceutical services, and active ingredients and proprietary products.
On a year-to-date basis, the company soared 52.5%, touching 52-week highs in December. In comparison, counterparts GlaxoSmithKline (GSK), Teva Pharmaceutical Industries (TEVA) and Pfizer (PFE) declined 7.4%, 7.9% and 3.3%, respectively. Industry giant Novartis (NVS) gained 8.6%.
The company recently signed a licensing, technology transfer, manufacturing and marketing agreement with R-Pharm of Russia, working on a profit-sharing model. During October, the company announced expansion of its products portfolio in the Russian and Ukraine markets through in-licensing deals with companies like Cipla and Vitabiotics. During early 2010, rumors that GSK was planning to acquire a 5% stake in Reddy's for almost $150 million-$160 million were disregarded as unlikely to happen. Furthermore, Dr. Reddy's also denied that it is seeking to sell its Indian formulations business to Pfizer.
During the first half of 2011, Dr. Reddy's is likely to close its deal with GlaxoSmithKline and complete the transfer of GSK's U.S. oral penicillin facility and product portfolio ownership rights. The transfer will likely add $40 million to the company's top line in 2011-2012.The company is looking for partnerships in order to enter the Japanese generic drugs markets. Japan offers vast opportunities, as the government is keen to make health care more affordable. Dr. Reddy's is forecasting sales of $1 billion in the U.S. by 2012-2013, up 42% from 2010 levels. The company aims to record $3 billion in revenue by 2013. Besides planning a single launch every year in the low competition/patent challenge segments, Dr. Reddy's has a pipeline of 12 first-to-file opportunities that provide six months exclusivity at launch. The market size of these products is valued at $9 billion.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
